Quick Answer
ZyVersa Therapeutics, Inc. reported Diluted EPS of $4.18 per share (loss) for fiscal year 2025.
ZyVersa Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$4.18 | +50.7% |
| 2024 | -$8.48 | +99.2% |
| 2023 | -$1089.70 | -375658.6% |
| 2022 | -$0.29 | +70.7% |
| 2022 | -$0.99 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.56 | -5.3% | -456.5% |
| June 30, 2025 | -$0.46 | +86.1% | +37.0% |
| March 31, 2025 | -$0.73 | +83.9% | +70.0% |
| September 30, 2024 | -$2.43 | +91.9% | +26.6% |
| June 30, 2024 | -$3.31 | +99.8% | +26.9% |
| March 31, 2024 | -$4.53 | +96.7% | +85.0% |
| September 30, 2023 | -$30.18 | — | +98.2% |
| June 30, 2023 | -$1694.12 | — | -1146.8% |
- ZyVersa Therapeutics, Inc. showed an increase of +50.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, ZyVersa Therapeutics, Inc.’s diluted eps has declined by 322.2% (from $0.99 per share (loss) to $4.18 per share (loss)).
- The most recent figure is from ZyVersa Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: